Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Visit our clinic at 1675 Alhambra Blvd Suite 2, Sacramento, or book mobile to any address in our service area.
Juraszek and Nalecz, 2019)
10.1158/1078-0432.CCR-19-3975 250 YangJ.ZhouY.XieS.WangJ.LiZ.ChenL.et al (2021)
61 AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE Yao-Chun Hsu 1 , Chi-Yi Chen 2 , Cheng-Hao Tseng 3 , Chieh-Chang Chen 4 , Teng-Yu Lee* 5 , Ming-Jong Bair 6 , Jyh-Jou Chen 7 , I-Wei Chang 8 , CHi-Yang Chang 9 , Ming-Shiang Wu 10 and Jaw-Town Lin 1 , (1)E-Da Hospital, (2)Ditmanson Medical Foundation Chiayi Christian Hospital, Chia Yi, Taiwan, (3)E-Da Cancer Hospital, I-Shou University, (4)National Taiwan University Hospital, (5)Taichung Veterans General Hospital, (6)Mackay Memorial Hospital-Taitung, (7)Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan, (8)Taipei Medical Universtiy, (9)Fu-Jen Catholic University, (10)Tainan Municipal Hospital Background: This study extends the follow-up of participants who completed a randomized placebo-controlled trial evaluating the safety and efficacy of tenofovir disoproxil fumarate (TDF) in reducing the risk of histological progression in patients with chronic hepatitis B (CHB) characterized by high viral load and minimally raised serum alanine aminotransferase (ALT) levels
AHK-Cu treatment was associated with decreased TGF-beta-1 secretion in dermal fibroblasts
US$ 27.05
.png)
US$ 25.74
US$ 23.55
US$ 28.03
US$ 28.70
US$ 25.60
US$ 27.01
US$ 21.89
US$ 29.88
US$ 23.26
